Taiwan Liposome Co (台灣微脂體), a developer of generic drugs used to treat breast and ovarian cancer, on Thursday said it had signed a research agreement with Belgian biotechnology company Ablynx NV.
Under their collaboration, the two firms will evaluate the potential of a novel antibody drug conjugate combining Taiwan Liposome’s immunoliposome drug delivery platform with Ablynx’s proprietary “Nanobody” drug technology.
Eventually, they hope to develop a product that has enhanced abilities to target and deliver cancer-killing drug payloads.
NANOBODIES
Ablynx is engaged mainly in the development of nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for treatment of inflammation, hematology, oncology and pulmonary diseases, according to information posted on the company’s Web site.
Using antibody drug conjugates to treat various types of cancer in recent years is aimed at generating fewer side effects, like hair loss, nausea and low blood pressure, than the older ways of using drugs.
DELIVERY TECHNOLOGY
Having worked on drug delivery technology since its establishment in 1997, Taiwan Liposome views using antibody drug conjugates as having great potential to increase efficacy in cancer and immune system treatments.
“Antibody drug conjugates have brought much excitement to the healthcare industry by combining the targeting specificity of antibodies with the efficacy of cytotoxic compounds,” company president George Yeh (葉志鴻) said in a press release.
“Our immunoliposome platform can drastically enhance the therapeutic value by carrying a much higher payload amount,” Yeh said. “This collaboration with Ablynx marks the starting point of infinite development possibilities for this technology platform.”
NO IMPACT
Yuanta Securities Group (元大證券) analyst Peggy Lee (李珮菁) yesterday said the collaboration is built on a feasibility study and is not expected to have a significant impact on the two firms in the short term, although they may receive milestone payments and royalties in the long term.
In the first three months of the year, Taiwan Liposome reported NT$35.99 million (US$1.19 million) in sales, down 53.39 percent from the same period last year, according to a company filing to the Taiwan Stock Exchange.
UNDERPERFORMING
Taiwan Liposome shares dropped 2.05 percent to NT$263 yesterday. They have declined 23.77 percent since the beginning of the year, underperforming the GRETAI, which has risen 12.18 percent over the same period.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure